Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction and Radiographic Bronchiectasis in Current and Former Smokers: A Cross-Sectional Study
To the Editor:
Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction is the major pathophysiologic defect leading to bronchiectasis in cystic fibrosis (CF) (1) . Recently published data indicated that cigarette smoking causes acquired CFTR dysfunction, manifested by increased sweat chloride (2) , altered sweat rate (3) , and reduced CFTR activity in the upper (4) and lower respiratory tracts (5) measured by nasal and lower airway potential difference, respectively, in subjects with chronic obstructive pulmonary disease (COPD) and smokers without fixed airflow obstruction. The defect continues despite smoking cessation, which may be related to smoking intensity (2) . COPDassociated bronchiectasis is a common COPD endotype, affecting between 25% and 69% of patients. It is identified by computed tomography (CT) and is associated with greater sputum production, poorer lung function, more frequent exacerbations, greater bacterial colonization, and worse outcomes compared with COPD patients without bronchiectasis (6, 7) . We hypothesized that acquired CFTR dysfunction in smokers would be associated with CT-identified bronchiectasis in patients with COPD, defining a particular subphenotype and an indicator of the clinical impact of CFTR dysfunction in individuals without CF.
Methods
This single-center study of current and former smokers without a known history of CF was conducted between January 1 and December 31, 2015, in participants previously enrolled in COPDGene (Genetic Epidemiology of COPD), a study intended to define subphenotypes of the disease (8) . We collected demographic data, body mass index, smoking status (current vs. former), smoking history in pack-years, and self-reported chronic bronchitis. Spirometry was performed according to American Thoracic Society/European Respiratory Society standards (9) , and severity of airflow limitation was grouped according to Global Initiative for Chronic Obstructive Lung Disease recommendations (10) . Inspiratory and expiratory volumetric computed tomographic scans were acquired using multidetector CT scanners and image reconstruction algorithms as previously reported (8) . The presence or absence of bronchiectasis was scored visually by a radiologist blinded to clinical characteristics as previously reported and validated by a second blinded scorer (11) . Bronchiectasis was defined by the presence of bronchial dilation (bronchial diameter greater than the diameter of the accompanying pulmonary vessel). Intraobserver agreement for visual bronchiectasis was good (Cohen's k = 0.746). Sweat chloride was measured by quantitative pilocarpine iontophoresis using the Macroduct collection system (Wescor) (2) . CFTR genetics were analyzed by complete CFTR sequencing if the sweat chloride level was abnormal (>40 mmol/L) (12) . Never smokers and subjects who had withdrawn from COPDGene were ineligible. Fisher's exact test and a nonparametric test (Wilcoxon rank-sum test) were used to assess the bivariate relationships between groups. The results were reported as median (interquartile range) for continuous variables. Statistical analyses were performed using SAS 9.4 software (SAS Institute 
Inc.). This study was approved by the University of Alabama at
Birmingham Institutional Review Board (F111209002), and all subjects provided written informed consent.
Results
Ninety-eight subjects were screened; 11 were excluded owing to the lifetime absence of smoking (n = 6) or because of missing radiologic data (n = 5). The baseline characteristics of the 87 subjects included in the study are presented in Table 1 . About onehalf (49%) of the cohort were current smokers with a median (interquartile range) 40 (30-57)-pack-year history. Postbronchodilator forced expiratory volume in 1 second (FEV 1 ) percent predicted was 67.5 (53-88), and FEV 1 /forced vital capacity ratio was 0.69 (0.5-0.78). Twelve (24%) of the patients had chronic bronchitis based on self-report; none used roflumilast, which can activate CFTR (13, 14) .
Twelve subjects (14%) had bronchiectasis visualized by CT. Among those with bronchiectasis, 33% had COPD defined by spirometry. Sweat chloride was measured in all subjects. The median (interquartile range) was 30 (13-43) mmol/L. Sweat chloride was greater in subjects with bronchiectasis than in individuals without bronchiectasis (44 [24. vs. 24 mmol/L; P = 0.03) (Figure 1 ). Elevated sweat chloride was associated with a 4.4-fold increased prevalence of visual bronchiectasis (prevalence ratio, 4.4; 95% confidence interval, 1.5, 13.5; P = 0.008). Among those with visual bronchiectasis, 8 (67%) of 12 patients had elevated sweat chloride (>40 mmol/L) (15), whereas 19 (25%) of 75 of those without bronchiectasis exceeded this threshold (P = 0.004). Elevated sweat chloride was also more common in subjects with mosaic attenuation visualized by CT (17) . CFTR variants of unknown significance (n = 5) were not more prevalent in patients with visual bronchiectasis. We also assessed for the presence of variants in the epithelial sodium channel genes (SCNN1A, SCNN1B, SCNN1D, and SCNN1G) and CA12, which are known or suspected to associate with bronchiectasis. Overall, seven patients had one or more variants in the epithelial sodium channel; these were not more prevalent in patients with visual bronchiectasis. The lack of detectable genetic contribution is consistent with experimental modeling (18) , although heterozygosity may serve as a susceptibility risk factor and should be evaluated in well-powered studies.
Discussion
CFTR dysfunction identified by elevated sweat chloride is associated with CT bronchiectasis among current and former smokers. To our knowledge, this is the first study to evaluate this relationship, and it suggests a possible underlying pathophysiologic mechanism that contributes to the development of bronchiectasis in COPD (and in smokers without recognized COPD). The degree of sweat chloride abnormality reflects a 20-30% decrement in CFTR function based on genotype-phenotype correlations, levels comparable to those of individuals with CF who have CFTR-related disorders that manifest with bronchiectasis later in life (19) . Of note, this association was independent of chronic bronchitis symptoms by self-report. In addition to bronchiectasis, mosaic attenuation visualized by high-resolution CT is a sign of airway disease by inducing gas trapping and heterogeneity of the parenchyma. The association of mosaic attenuation with elevated sweat chloride further supports the concept that CFTR abnormality may contribute to airway disease. Of note, air trapping was rapidly reversible in G551D CFTR patients with CF with administration of the CFTR potentiator ivacaftor (20) .
Our study has important implications for the understanding of the relationship between acquired CFTR dysfunction and CT bronchiectasis. Smoke-induced acquired CFTR dysfunction should be considered when evaluating the etiology of bronchiectasis, especially when patients have elevated sweat chloride but normal CFTR genetic analysis. Recent studies suggested that CFTR potentiators can reverse acquired CFTR abnormalities in vitro (2, 4, 21, 22) and that ivacaftor may restore CFTR function and improve symptoms in patients with COPD with chronic bronchitis (22) . Thus, these results have potential therapeutic implications, given that CFTR potentiators used for treatment of CF may also restore CFTR activity in patients with COPD (22) .
Limitations of the present study to consider include the observational design; the relatively small number of individuals with bronchiectasis; and that alternative etiologies of bronchiectasis, such as infection, immunodeficiency, and chronic aspiration (23), were not available for evaluation. Although our study did not reveal an association of bronchiectasis with lung function or chronic bronchitis (2, 4, 21, 22) , the present analysis was underpowered for this analysis. The potential for CFTR dysfunction to contribute to worsened airway disease in patients with smoking-related lung disease and to identify a specific subphenotype warrants further investigation.
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Obstructive Sleep Apnea with Chronic Obstructive Pulmonary Disease among Medicare Beneficiaries
The term "overlap syndrome" was introduced to describe the coexistence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) in a single individual (1), and it is associated with a severe clinical course. An OSA-related nocturnal desaturation is more profound in the presence of COPD, and daytime hypoxemia due to COPD is worse in the presence of OSA (2). Patients with overlap syndrome are far more likely to develop pulmonary hypertension and right heart failure than patients with either condition alone (3, 4). As a result, patients with overlap syndrome have significantly worse quality of life, greater risk of morbidity and mortality, and a substantially higher medical care use and cost than those with either diagnosis independently (5-7). We conducted a claims-based study of Medicare beneficiaries to examine the diagnosed prevalence and trend of overlap syndrome, as well as its patient characteristics. All patients with COPD were identified as previously reported (9) . Exclusion criteria were age 65 years or younger, residence in a nursing facility or enrollment in a health maintenance organization plan, or lack of completed enrollment in Medicare parts A and B for 12 months or longer or until death in Supported by Agency for Healthcare Research and Quality grants R01-HS020642 and R24-HS022134.
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